vs

Side-by-side financial comparison of FATE THERAPEUTICS INC (FATE) and Beyond Air, Inc. (XAIR). Click either name above to swap in a different company.

Beyond Air, Inc. is the larger business by last-quarter revenue ($2.2M vs $1.4M, roughly 1.6× FATE THERAPEUTICS INC). On growth, Beyond Air, Inc. posted the faster year-over-year revenue change (104.7% vs -26.4%). Beyond Air, Inc. produced more free cash flow last quarter ($-4.3M vs $-112.0M). Over the past eight quarters, Beyond Air, Inc.'s revenue compounded faster (116.1% CAGR vs -15.7%).

Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.

Delta Air Lines, Inc. is a major airline in the United States headquartered in Atlanta, Georgia, operating nine hubs, with Hartsfield–Jackson Atlanta International Airport being its largest in terms of total passengers and number of departures. With its regional subsidiaries and contractors operating under the brand name Delta Connection, Delta has over 5,400 flights daily and serves 325 destinations in 52 countries on six continents.

FATE vs XAIR — Head-to-Head

Bigger by revenue
XAIR
XAIR
1.6× larger
XAIR
$2.2M
$1.4M
FATE
Growing faster (revenue YoY)
XAIR
XAIR
+131.1% gap
XAIR
104.7%
-26.4%
FATE
More free cash flow
XAIR
XAIR
$107.8M more FCF
XAIR
$-4.3M
$-112.0M
FATE
Faster 2-yr revenue CAGR
XAIR
XAIR
Annualised
XAIR
116.1%
-15.7%
FATE

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
FATE
FATE
XAIR
XAIR
Revenue
$1.4M
$2.2M
Net Profit
$-7.3M
Gross Margin
13.7%
Operating Margin
-300.6%
Net Margin
-334.4%
Revenue YoY
-26.4%
104.7%
Net Profit YoY
37.9%
43.7%
EPS (diluted)
$-0.85

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FATE
FATE
XAIR
XAIR
Q4 25
$1.4M
$2.2M
Q3 25
$1.7M
$1.8M
Q2 25
$1.9M
$1.8M
Q1 25
$1.6M
$1.2M
Q4 24
$1.9M
$1.1M
Q3 24
$3.1M
$798.0K
Q2 24
$6.8M
$683.0K
Q1 24
$1.9M
$470.0K
Net Profit
FATE
FATE
XAIR
XAIR
Q4 25
$-7.3M
Q3 25
$-32.3M
$-7.9M
Q2 25
$-34.1M
$-7.7M
Q1 25
$-37.6M
$-8.0M
Q4 24
$-13.0M
Q3 24
$-47.7M
$-13.4M
Q2 24
$-38.4M
$-12.2M
Q1 24
$-48.0M
$-13.7M
Gross Margin
FATE
FATE
XAIR
XAIR
Q4 25
13.7%
Q3 25
-16.4%
Q2 25
8.9%
Q1 25
-2.8%
Q4 24
-20.1%
Q3 24
-135.8%
Q2 24
-48.6%
Q1 24
-109.4%
Operating Margin
FATE
FATE
XAIR
XAIR
Q4 25
-300.6%
Q3 25
-1995.1%
-421.4%
Q2 25
-1938.5%
-432.8%
Q1 25
-2534.1%
-622.6%
Q4 24
-1021.6%
Q3 24
-1703.9%
-1608.1%
Q2 24
-665.7%
-1988.3%
Q1 24
-2652.9%
-2687.9%
Net Margin
FATE
FATE
XAIR
XAIR
Q4 25
-334.4%
Q3 25
-1852.4%
-436.7%
Q2 25
-1786.6%
-437.0%
Q1 25
-2309.5%
-697.4%
Q4 24
-1215.7%
Q3 24
-1551.0%
-1673.9%
Q2 24
-567.4%
-1786.4%
Q1 24
-2493.7%
-2916.4%
EPS (diluted)
FATE
FATE
XAIR
XAIR
Q4 25
$-0.85
Q3 25
$-0.27
$-1.25
Q2 25
$-0.29
$-1.53
Q1 25
$-0.32
$13.26
Q4 24
$-2.96
Q3 24
$-0.40
$-5.67
Q2 24
$-0.33
$-5.32
Q1 24
$-0.47
$-0.36

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FATE
FATE
XAIR
XAIR
Cash + ST InvestmentsLiquidity on hand
$203.7M
$11.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$207.2M
$8.1M
Total Assets
$318.9M
$36.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FATE
FATE
XAIR
XAIR
Q4 25
$203.7M
$11.7M
Q3 25
$215.4M
$10.7M
Q2 25
$222.8M
$6.5M
Q1 25
$240.4M
$6.9M
Q4 24
$279.1M
$10.9M
Q3 24
$296.9M
$28.4M
Q2 24
$304.9M
$21.4M
Q1 24
$121.3M
$34.5M
Total Debt
FATE
FATE
XAIR
XAIR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$11.8M
Q3 24
$12.5M
Q2 24
$17.5M
Q1 24
$17.5M
Stockholders' Equity
FATE
FATE
XAIR
XAIR
Q4 25
$207.2M
$8.1M
Q3 25
$234.1M
$12.7M
Q2 25
$261.4M
$9.9M
Q1 25
$288.4M
$13.6M
Q4 24
$318.7M
$17.6M
Q3 24
$362.3M
$28.1M
Q2 24
$397.0M
$16.1M
Q1 24
$426.1M
$25.0M
Total Assets
FATE
FATE
XAIR
XAIR
Q4 25
$318.9M
$36.8M
Q3 25
$343.7M
$31.0M
Q2 25
$371.6M
$28.1M
Q1 25
$398.7M
$30.1M
Q4 24
$440.7M
$34.1M
Q3 24
$495.0M
$53.0M
Q2 24
$528.8M
$46.5M
Q1 24
$569.9M
$57.0M
Debt / Equity
FATE
FATE
XAIR
XAIR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.67×
Q3 24
0.44×
Q2 24
1.08×
Q1 24
0.70×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FATE
FATE
XAIR
XAIR
Operating Cash FlowLast quarter
$-106.1M
$-4.2M
Free Cash FlowOCF − Capex
$-112.0M
$-4.3M
FCF MarginFCF / Revenue
-8183.9%
-193.8%
Capex IntensityCapex / Revenue
434.8%
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-199.6M
$-22.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FATE
FATE
XAIR
XAIR
Q4 25
$-106.1M
$-4.2M
Q3 25
$-24.4M
$-4.5M
Q2 25
$-24.6M
$-4.5M
Q1 25
$-33.8M
$-7.0M
Q4 24
$-122.9M
$-7.7M
Q3 24
$-29.4M
$-13.3M
Q2 24
$-32.3M
$-10.2M
Q1 24
$-33.4M
$-10.7M
Free Cash Flow
FATE
FATE
XAIR
XAIR
Q4 25
$-112.0M
$-4.3M
Q3 25
$-26.6M
$-4.7M
Q2 25
$-25.9M
$-4.7M
Q1 25
$-35.0M
$-8.5M
Q4 24
$-123.6M
$-8.3M
Q3 24
$-29.9M
$-14.5M
Q2 24
$-32.4M
$-12.9M
Q1 24
$-33.4M
$-12.7M
FCF Margin
FATE
FATE
XAIR
XAIR
Q4 25
-8183.9%
-193.8%
Q3 25
-1526.5%
-258.5%
Q2 25
-1360.7%
-268.4%
Q1 25
-2148.9%
-733.9%
Q4 24
-6645.4%
-771.5%
Q3 24
-973.1%
-1819.9%
Q2 24
-477.8%
-1881.8%
Q1 24
-1736.9%
-2692.8%
Capex Intensity
FATE
FATE
XAIR
XAIR
Q4 25
434.8%
1.5%
Q3 25
126.5%
13.5%
Q2 25
71.4%
11.3%
Q1 25
73.4%
130.0%
Q4 24
39.2%
50.1%
Q3 24
16.1%
147.2%
Q2 24
0.8%
391.4%
Q1 24
4.5%
410.9%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons